Pasithea Therapeutics Corp.
KTTAHealthcare|Biotechnology|US
$0.58
+0.06 (+11.31%)
DCF Value
$7.85
Tangible Book / Share
$6.60
Cash / Share
$6.49
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06961565 PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | NF1 Mutation, Neurofibroma Plexiform | P1 | Recruiting | 56 | Open-label | PAS-004 Tablets, PAS-004 Capsule |
| NCT06299839 PAS-004 in Patients With Advanced Solid Tumors | RAS Mutation, NF1 Mutation | P1 | Recruiting | 83 | Open-label | PAS-004 Capsules, PAS-004 Tablets |